In last trading session, Agios Pharmaceuticals Inc (NASDAQ:AGIO) saw 0.36 million shares changing hands with its beta currently measuring 0.77. Company’s recent per share price level of $29.45 trading at $0.19 or 0.65% at ring of the bell on the day assigns it a market valuation of $1.69B. That closing price of AGIO’s stock is at a discount of -112.5% from its 52-week high price of $62.58 and is indicating a premium of 20.48% from its 52-week low price of $23.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 681.08K if we extend that period to 3-months.
For Agios Pharmaceuticals Inc (AGIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.76 in the current quarter.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) trade information
Upright in the green during last session for gaining 0.65%, in the last five days AGIO remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $29.45 price level, adding 1.44% to its value on the day. Agios Pharmaceuticals Inc’s shares saw a change of -10.38% in year-to-date performance and have moved 6.47% in past 5-day. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a performance of -3.12% in past 30-days. Number of shares sold short was 3.55 million shares which calculate 5.51 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 51 to the stock, which implies a rise of 42.25% to its current value. Analysts have been projecting 51 as a low price target for the stock while placing it at a high target of 51. It follows that stock’s current price would drop -73.17% in reaching the projected high whereas dropping to the targeted low would mean a loss of -73.17% for stock’s current value.
Agios Pharmaceuticals Inc (AGIO) estimates and forecasts
This year revenue growth is estimated to rise 39.73% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.73M for the same. And 7 analysts are in estimates of company making revenue of 10.22M in the next quarter. Company posted 8.19M and 8.62M of sales in current and next quarters respectively a year earlier.
Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s Major holders
Insiders are in possession of 1.52% of company’s total shares while institution are holding 108.50 percent of that, with stock having share float percentage of 110.17%. Investors also watch the number of corporate investors in a company very closely, which is 108.50% institutions for Agios Pharmaceuticals Inc that are currently holding shares of the company. FARALLON CAPITAL MANAGEMENT LLC is the top institutional holder at AGIO for having 5.65 million shares of worth $243.82 million. And as of 2024-06-30, it was holding 9.9547 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.5 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6769 of outstanding shares, having a total worth of $237.02 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.77 shares of worth $52.1 million or 3.09% of the total outstanding shares. The later fund manager was in possession of 1.49 shares on Mar 31, 2025 , making its stake of worth around $43.76 million in the company or a holder of 2.59% of company’s stock.
